Beigene's Inspections Delay Suggest Eventual Approval, Says This Analyst

  • Beigene Limited BGNE provided a regulatory update on the anticipated US approval decision for the Biological License Application for tislelizumab in 2L metastatic esophageal squamous cell carcinoma (ESCC). 
  • With the BLA filing initially having a PDUFA date of July 12, the FDA deferred action on the decision, as they have been unable to conduct required inspections in China due to recent COVID-19 travel restrictions. 
  • SVB Leerink notes that BGNE did not receive a Complete Response Letter (CRL), and the application remains under review. 
  • The company indicated that a new action date had not been provided by the FDA, as the public health situation in China continues to evolve. 
  • BGNE and partner Novartis AG NVS will work closely with the agency to help schedule the inspections when possible. 
  • SVB thinks the reason for the decision may be favorable for some investors, as there has been speculation that the agency may view data from China unfavorably.
  • "Therefore, the decision to delay the application versus issuing a CRL and terminating the review cycle could be viewed as a positive." the analysts added.
  • Price Action: BGNE shares are up 2.69% at $174.30 during the market session on the last check Thursday.
Price Target
Posted In: Analyst ColorBiotechNewsHealth CareFDAAnalyst RatingsGeneralBriefs